E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Non-24 Hour Sleep-Wake Disorder |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10013419 |
E.1.2 | Term | Disruptions of 24 hour sleep-wake cycle |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To characterize the effect of tasimelteon, 20 mg/night for 52 weeks, on standard measures of patients' safety. |
|
E.2.2 | Secondary objectives of the trial |
To assess the effect of tasimelteon on patient reported nighttime sleep as measured by a Patient Global Impression of Change (PGI-C).
To assess the effect of tasimelteon on daytime naps as measured by Patient Global Impression of Change (PGI-C).
To assess the effects of tasimelteon as measured by a Clinical Global Impression of Change (CGI-C). |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Pharmacogenomic Sub-Study Protocol, final version dated from 22 June 2010
Objectives :
Identify genetic markers that may be associated the regulation of the circadian rythm or sleep.
Identify genetic markers that correlate with adverse events that may occur upon treatment with tasimelteon.
Identify genetic markers that correlate with response to tasimelteon treatment.
|
|
E.3 | Principal inclusion criteria |
1.Ability and acceptance to provide informed consent; 2.Men or women between 18 – 75 years, inclusive; 3.Body Mass Index (BMI) of ≥ 18 and ≤ 33 kg/m2 (BMI = weight (kg)/ [height (m)]2); 4.Males, non-fecund females, or females of child-bearing potential ( defined as less than 1 year post-menopausal or not surgically sterile ) must be using an acceptable method of birth control (e.g., oral contraceptives, patch, intrauterine device [IUD], diaphragm or condom with spermicidal jelly or foam or abstinence, or cervical cap) for a period of 35 days before the first dosing and must have a negative pregnancy test at the screening and baseline visits; 5.Note: Women using hormonal methods of birth control (e.g. oral contraceptives, patch, and steroids) must use an additional method of birth control during the study and for one month after the last dose. 6.Willing and able to comply with study requirements and restrictions; 7.No perception of light by the patient’s own report; 8.Diagnosis of N24HSWD a.History (within the last 3 months) of trouble sleeping at night (difficulty initiating sleep or staying asleep), difficulty awakening in the morning, or daytime sleepiness as determined by answering yes to at least one question in the Sleep Complaint Questionnaire; b.An abnormal phase relationship between the circadian melatonin rhythm and their target sleep-wake cycle is established per urinary aMT6s assessment. 9. Affiliated with or beneficiary of a social security system
|
|
E.4 | Principal exclusion criteria |
1. Have a probable diagnosis of a current sleep disorder other than N24HSWD that is the primary cause of the sleep disturbance based on clinical investigator medical judgment; 2. History (within the 12 months prior to screening) of psychiatric disorders including Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures; 3. History of intolerance and/or hypersensitivity to melatonin or melatonin agonists; 4. History of drug or alcohol abuse as defined in DSM-IV, Diagnostic Criteria for Drug and Alcohol Abuse, within the 12 months prior to screening and/or regular consumption of alcoholic drinks (> 40g/day); 5. Patients having any current suicidal ideation of type 4 or 5 on the C-SSRS at Screening or Baseline; 6. Patient is at risk of suicide, in the opinion of the Investigator. Evidence of suicide risk could include any suicide attempt within the past year or any other suicidal behavior within the past year; 7. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction unless currently controlled and stable; 8. Patients who have estimated creatinine clearance (CLcr; based on the Cockcroft-Gault equation) ≤ to 55 mL/min; 9. Clinically significant deviation from normal in clinical laboratory results, vital signs measurements, or physical examination findings at screening or baseline as determined by the clinical investigator; 10. Indication of impaired liver function (values for AST, ALT or bilirubin > 2 times Upper Limit of Normal); 11. Pregnant or lactating females; 12. A positive test for drugs of abuse at the screening visit; 13. Smoke more than 10 cigarettes/day; 14. Participation in a previous tasimelteon (aka VEC-162 or BMS-214778) trial; 15. Exposure to any investigational drug, including placebo, within 30 days, 5 half-lives, or the exclusion period given by a previous study in which the patient has participated in, whichever of the three scenarios is longer. 16.Use of central nervous system prescription or OTC medications, other than melatonin, that affects the sleep-wake cycle within 3 weeks or 5 half-lives (whichever was longer) of Baseline; 17. Use of melatonin or melatonin agonist within 1 week of the urine collection for the aMT6s assessment; 18. Any other sound medical reason as determined by the clinical investigator.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Adverse events including suicidal ideation or behavior, changes in vital signs, clinical laboratory evaluations, electrocardiograms and physical exam findings during treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |